down arrow

Owens & Minor, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6907321029
USD
2.03
-0.08 (-3.79%)

Jan 26

NYS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.022.19

52 Week

1.8415.54
Valuation
Technical
Day's Volume

CASH

879.01 k

Shareholding (Sep 2025)

FII

9.46%

Held by 103 FIIs

DII

17.64%

Held by 78 DIIs

Promoter

6.37%

How big is Owens & Minor, Inc.?

22-Jun-2025

As of Jun 18, Owens & Minor, Inc. has a market capitalization of 577.67 million and reported net sales of 10,720.25 million with a net profit of -365.78 million over the latest four quarters. Shareholder's funds are 565.23 million, and total assets amount to 4,656.16 million.

As of Jun 18, Owens & Minor, Inc. has a market capitalization of 577.67 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 10,720.25 million, while the sum of net profit for the same period is -365.78 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 565.23 million, and total assets amount to 4,656.16 million.

View full answer

What does Owens & Minor, Inc. do?

22-Jun-2025

Owens & Minor, Inc. is a healthcare solutions company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $2.632 billion and a market cap of $577.67 million. The company reported a net profit loss of $25 million as of March 2025.

Overview:<BR>Owens & Minor, Inc. is a healthcare solutions company operating in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,632 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 577.67 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 6.00 <BR>Debt Equity: 3.31 <BR>Return on Equity: 19.43% <BR>Price to Book: 1.01<BR><BR>Contact Details:<BR>Address: 9120 LOCKWOOD BLVD, MECHANICSVILLE VA: 23116 <BR>Tel: 1 804 7237000, 1 804 7237556 <BR>Fax: 1 804 7237100 <BR>Website: http://www.owens-minor.com/

View full answer

Who are in the management team of Owens & Minor, Inc.?

22-Jun-2025

As of March 2022, the management team of Owens & Minor, Inc. includes Independent Chairman Robert Sledd, CEO Edward Pesicka, and several independent directors: Mark Beck, Lt. Gen. Gwendolyn Bingham, Robert Henkel, Mark McGettrick, and Eddie Moore. This team combines executive leadership with independent oversight.

As of March 2022, the management team of Owens & Minor, Inc. includes the following individuals:<BR><BR>- Mr. Robert Sledd, who serves as the Independent Chairman of the Board.<BR>- Mr. Edward Pesicka, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Mark Beck, who is an Independent Director.<BR>- Lt. Gen. Gwendolyn Bingham, who is also an Independent Director.<BR>- Mr. Robert Henkel, serving as an Independent Director.<BR>- Mr. Mark McGettrick, who is an Independent Director.<BR>- Mr. Eddie Moore, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance of the company.

View full answer

Is Owens & Minor, Inc. overvalued or undervalued?

20-Sep-2025

As of May 5, 2023, Owens & Minor, Inc. is considered overvalued with a valuation grade of risky, reflected by its low growth metrics and significant underperformance of -57.54% year-to-date compared to the S&P 500's 12.22% return.

As of 5 May 2023, the valuation grade for Owens & Minor, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 6, an EV to EBITDA of 4.76, and a PEG ratio of 0.14, which suggests limited growth prospects relative to its price. In comparison to peers, Owens & Minor has a higher P/E ratio than Pacific Biosciences of California, Inc., which has a P/E of -0.6779, highlighting a relative overvaluation.<BR><BR>The stock has significantly underperformed against the S&P 500, with a year-to-date return of -57.54% compared to the index's 12.22%. This stark contrast reinforces the notion that Owens & Minor, Inc. is currently overvalued in the market.

View full answer

Is Owens & Minor, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Owens & Minor, Inc. is in a bearish trend, indicated by negative MACD readings, moving averages, and KST, with a year-to-date return of -57.54% compared to the S&P 500's 12.22%.

As of 5 August 2025, the technical trend for Owens & Minor, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish MACD readings on both the weekly and monthly charts, bearish moving averages on the daily timeframe, and a bearish KST on both weekly and monthly periods. Additionally, the Bollinger Bands and OBV are showing mildly bearish signals. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -57.54% versus the S&P 500's 12.22%, and a one-year return of -64.90% compared to 17.14% for the benchmark.

View full answer

Compare Owens & Minor, Inc. with Similar Stocks

Tandem Diabetes Care, Inc.Alphatec Holdings, Inc.PROCEPT BioRobotics Corp.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Weak Long Term Fundamental Strength with a 20.30% CAGR growth in Operating Profits over the last 5 years

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.13 times
  • The company has been able to generate a Return on Capital Employed (avg) of 11.05% signifying low profitability per unit of total capital (equity and debt)
2

Negative results in Jun 25

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 166 Million (Micro Cap)

stock-summary
P/E

6.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-4.96

stock-summary
Return on Equity

-41.73%

stock-summary
Price to Book

-0.39

Revenue and Profits:
Net Sales:
697 Million
(Quarterly Results - Sep 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-63.16%
0%
-63.16%
6 Months
-74.24%
0%
-74.24%
1 Year
-86.41%
0%
-86.41%
2 Years
-89.85%
0%
-89.85%
3 Years
-90.07%
0%
-90.07%
4 Years
-95.16%
0%
-95.16%
5 Years
-92.45%
0%
-92.45%

Owens & Minor, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Owens & Minor, Inc. Hits New 52-Week Low at $3.76

Owens & Minor, Inc. Hits New 52-Week Low at $3.76

Owens & Minor, Inc. has reached a new 52-week low, reflecting significant challenges within the company. With a market capitalization of USD 416 million, it shows troubling financial metrics, including a negative return on equity and high debt levels, raising concerns about its long-term viability in the Pharmaceuticals & Biotechnology sector.

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.49%
EBIT Growth (5y)
20.30%
EBIT to Interest (avg)
3.42
Debt to EBITDA (avg)
4.13
Net Debt to Equity (avg)
3.31
Sales to Capital Employed (avg)
3.80
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.05%
ROE (avg)
16.41%

Valuation key factors

Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
1.07
EV to EBIT
9.13
EV to EBITDA
4.76
EV to Capital Employed
1.02
EV to Sales
0.23
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
11.14%
ROE (Latest)
19.43%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 71 Schemes (66.45%)

Foreign Institutions

Held by 103 Foreign Institutions (9.46%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 2.26% vs -74.09% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 93.32% vs -235.20% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "697.30",
          "val2": "681.90",
          "chgp": "2.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "93.20",
          "val2": "108.70",
          "chgp": "-14.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "30.00",
          "val2": "45.20",
          "chgp": "-33.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.70",
          "val2": "-195.40",
          "chgp": "98.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.60",
          "val2": "-83.80",
          "chgp": "93.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "41.80%",
          "val2": "72.30%",
          "chgp": "-3.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.55% vs 3.80% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -778.21% vs -284.37% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,700.90",
          "val2": "10,334.00",
          "chgp": "3.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "526.30",
          "val2": "497.90",
          "chgp": "5.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "151.60",
          "val2": "167.60",
          "chgp": "-9.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-457.00",
          "val2": "-95.60",
          "chgp": "-378.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-362.70",
          "val2": "-41.30",
          "chgp": "-778.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.40%",
          "val2": "20.40%",
          "chgp": "0.40%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
697.30
681.90
2.26%
Operating Profit (PBDIT) excl Other Income
93.20
108.70
-14.26%
Interest
30.00
45.20
-33.63%
Exceptional Items
-2.70
-195.40
98.62%
Consolidate Net Profit
-5.60
-83.80
93.32%
Operating Profit Margin (Excl OI)
41.80%
72.30%
-3.05%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 2.26% vs -74.09% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 93.32% vs -235.20% in Jun 2025

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
10,700.90
10,334.00
3.55%
Operating Profit (PBDIT) excl Other Income
526.30
497.90
5.70%
Interest
151.60
167.60
-9.55%
Exceptional Items
-457.00
-95.60
-378.03%
Consolidate Net Profit
-362.70
-41.30
-778.21%
Operating Profit Margin (Excl OI)
24.40%
20.40%
0.40%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 3.55% vs 3.80% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -778.21% vs -284.37% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Owens & Minor, Inc. stock-summary
stock-summary
Owens & Minor, Inc.
Pharmaceuticals & Biotechnology
Owens & Minor, Inc. is a healthcare solutions company with integrated technologies, products and services. The Company operates through two segments: Global Solutions and Global Products. Global Solutions segment includes its United States distribution, outsourced logistics and value-added services business. Global Products manufactures and sources medical surgical products through its production and kitting operations. Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes products purchased from manufacturers and its own proprietary products. Global Products segment provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. Its manufacturing facilities are located in the United States, Thailand, Honduras, Mexico and Ireland.
Company Coordinates stock-summary
Company Details
9120 LOCKWOOD BLVD , MECHANICSVILLE VA : 23116
stock-summary
Tel: 1 804 72370001 804 7237556
stock-summary
http://www.owens-minor.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."